Century Therapeutics Inc
Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19… Read more
Century Therapeutics Inc (IPSC) - Total Assets
Latest total assets as of September 2025: $244.72 Million USD
Based on the latest financial reports, Century Therapeutics Inc (IPSC) holds total assets worth $244.72 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Century Therapeutics Inc - Total Assets Trend (2015–2024)
This chart illustrates how Century Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Century Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Century Therapeutics Inc's total assets of $244.72 Million consist of 54.9% current assets and 45.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.6% |
| Accounts Receivable | $1.52 Million | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $34.20 Million | 9.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Century Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Century Therapeutics Inc's current assets represent 54.9% of total assets in 2024, an increase from 0.0% in 2015.
- Cash Position: Cash and equivalents constituted 16.6% of total assets in 2024, up from 0.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 4.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 9.7% of total assets.
Century Therapeutics Inc Competitors by Total Assets
Key competitors of Century Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Century Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Century Therapeutics Inc generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Century Therapeutics Inc is currently not profitable relative to its asset base.
Century Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.25 | 10.39 | 6.51 |
| Quick Ratio | 6.25 | 10.46 | 6.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $115.68 Million | $ 186.19 Million | $ 66.69 Million |
Century Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Century Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.87 |
| Latest Market Cap to Assets Ratio | 0.32 |
| Asset Growth Rate (YoY) | -2.1% |
| Total Assets | $353.22 Million |
| Market Capitalization | $112.43 Million USD |
Valuation Analysis
Below Book Valuation: The market values Century Therapeutics Inc's assets below their book value (0.32 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Century Therapeutics Inc's assets decreased by 2.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Century Therapeutics Inc (2015–2024)
The table below shows the annual total assets of Century Therapeutics Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $353.22 Million | -2.07% |
| 2023-12-31 | $360.69 Million | -25.87% |
| 2022-12-31 | $486.54 Million | +11.24% |
| 2021-12-31 | $437.38 Million | +309.62% |
| 2020-12-31 | $106.78 Million | +17.47% |
| 2019-12-31 | $90.90 Million | -88.01% |
| 2016-12-31 | $758.00 Million | -10.26% |
| 2015-12-31 | $844.70 Million | -- |